Get past bacterial resistance with ocular antibiotic armamentarium

Article

Continued evolution in the landscape of bacterial resistance and antimicrobial agents is mandating careful prescribing of anti-infective medications to optimize success in prophylactic and therapeutic indications and to minimize future problems associated with pathogen resistance.

"The first successful clinical use of an antibiotic was 80 years ago and was for an ocular infection. We've come a long way since then in developing new antibiotics with new mechanisms of action, but we have also managed to use these agents in ways where many no longer work," noted Dr. May, who is in private practice in northern Mississippi and serves as adjunct faculty for Southern College of Optometry, Memphis, TN.

Dr. May explained that subtherapeutic and long-term dosing are both culprits in promoting bacterial resistance so that it is important to not taper antibiotic treatment regimens and use only a short-term course when prescribing an anti-infective agent as surgical prophylaxis.

Antimicrobial choices

Currently, fluoroquinolones are the most widely used anti-infective agents for ocular infections. However, older peptide antibiotics, bacitracin and polymixin B, and folic acid synthesis inhibitors, such as sulfacetamide and trimethoprim, can be a useful and cost-effective option in appropriately selected situations.

Proper prescribing depends on understanding the spectrum of activity of the various agents and whether they are bacteriostatic or bactericidal.

The folic acid synthesis inhibitors are bacteriostatic agents that have good activity against gram-positive bacteria. However, these agents should not be used in anyone with known sulfonamide sensitivity or in the management of more serious infections because they are bacteriostatic agents.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.
Clark Chang, OD, MSA, MSc, FAAO, gave a presentation alongside Susan Gromacki, OD, MS, FAAO, FSLS, at this year's Optometry's Meeting.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
© 2025 MJH Life Sciences

All rights reserved.